

CLAIMS

What is claimed is:

- 5 1. A method for treating an inflammatory condition comprising administering to a subject in need of such treatment a molecule comprising an oligopeptide peptide or functional analogue thereof said molecule capable of reducing production of NO by a cell.
2. A method for treating an inflammatory condition comprising administering to a subject in need of such treatment a molecule comprising an oligopeptide peptide or functional analogue thereof wherein said molecule is capable of modulating translocation and/or activity of a gene transcription factor present in a cell.
- 10 3. The method according to claim 1 wherein said molecule additionally is capable of modulating translocation and/or activity of a gene transcription factor present in a cell.
- 15 4. The method according to claim 2 or 3 wherein said gene transcription factor comprises a NF-kappaB/Rel protein.
5. The method according to claim 3 wherein said modulating translocation and/or activity of a gene transcription factor allows modulation of TNF-alpha production by said cell.
- 20 6. The method according to claim 5 wherein said TNF-alpha production is reduced.
7. The method according to any one of claims 1 to 6 wherein said inflammatory condition comprises an acute inflammatory condition.
8. The method according to claim 7 wherein said acute inflammatory condition comprises anthrax.
- 25 9. The method according to any one of claims 1 to 8 wherein said molecule is selected from table 6.
10. The method according to any one of claims 1 to 9 wherein said treatment comprises administering to said subject a pharmaceutical composition comprising an oligopeptide or functional analogue thereof capable of reducing production of NO by a cell.
- 30 11. The method according to claim 10 wherein said composition comprises at least two oligopeptides or functional analogues thereof capable of reducing production of NO by a cell.

12. The method according to claim 11 wherein said at least two oligopeptides are selected from the group LQGV, AQGV and VLPALP.

13. An isolated oligopeptide or functional analogue thereof capable of reducing production of NO by a cell.

5 14. A pharmaceutical composition comprising an oligopeptide or functional analogue according to claim 13.

15. The composition of claim 14 comprising at least two oligopeptides or functional analogues thereof capable of reducing production of NO by a cell.

10 16. A method of treating an inflammatory condition in a subject by reducing NO production by the subject's macrophages, the method comprising administering to the subject an oligopeptide or functional analogue thereof capable of reducing production of NO by a cell.